Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vijay Singh

Rheumatology Sewell, NJ Medical Doctor

NPI 1174786297 CMS profile 143998

123 Egg Harbor Rd, Suite 804, Sewell, NJ 08080

Open in the dashboard

General payments

$7,545

499 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vijay Singh of Sewell, NJ is reported in the CMS Open Payments database as having received $7,545 across 499 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,443 98
2024 General $1,813 116
2023 General $2,121 126
2022 General $856 55
2021 General $302 22
2020 General $225 15
2019 General $785 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vijay Singh
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Vijay Singh were reported at $1,443. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Vijay Singh Rheumatology median Middle half National median
2019 $785 $744 $153–$2,687 $163
2020 $225 $462 $98–$2,027 $114
2021 $302 $531 $101–$2,153 $132
2022 $856 $627 $125–$2,303 $149
2023 $2,121 $741 $145–$2,524 $160
2024 $1,813 $830 $166–$2,660 $164
2025 $1,443 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,408 104 payments
  2. Amgen Inc. $949 68 payments
  3. UCB, Inc. $779 55 payments
  4. Janssen Biotech, Inc. $620 33 payments
  5. ANI Pharmaceuticals, Inc. $580 24 payments
  6. AstraZeneca Pharmaceuticals LP $465 30 payments
  7. Novartis Pharmaceuticals Corporation $462 27 payments
  8. E.R. Squibb & Sons, L.L.C. $399 33 payments
  9. Pfizer Inc. $383 28 payments
  10. GlaxoSmithKline, LLC. $286 20 payments
  11. Other $1,214 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,359 495 payments
  2. Education $186 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $745 56 payments
  2. Cimzia $503 38 payments
  3. TREMFYA $470 22 payments
  4. PURIFIED CORTROPHIN GEL $460 17 payments
  5. SAPHNELO $437 28 payments
  6. SKYRIZI $427 28 payments
  7. ORENCIA $399 33 payments
  8. XELJANZ $368 27 payments
  9. EVENITY $289 28 payments
  10. BENLYSTA $286 20 payments
  11. Other $4,009 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

6,533

Median for Rheumatology: 1,511

Drug cost

$5,903,080

Median for Rheumatology: $1,139,948

Branded share of claims

30.2%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 114 $920,378
Remicade Infliximab Brand 104 $779,196
Cimzia (2 Pack) Certolizumab Pegol Brand 88 $611,942
Benlysta Belimumab Brand 154 $508,189
Enbrel Sureclick Etanercept Brand 59 $466,501
Prolia Denosumab Brand 240 $428,090
Orencia Abatacept/Maltose Brand 81 $407,571
Simponi Aria Golimumab Brand 48 $332,077
Cosentyx Sensoready (2 Pens) Secukinumab Brand 17 $202,904
Actemra Tocilizumab Brand 40 $183,686

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$1,942,421

Of which drugs: $1,564,795

Medicare patients

911

Average age 73

Services billed

200,202

704 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 47%
Diabetes 31%
Ischemic heart disease 24%
Depression 24%
Chronic kidney disease 22%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 30 13,375 $450,808
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 44 121,200 $429,254
Injection, denosumab, 1 mg J0897 Office 218 20,940 $426,158
Injection, golimumab, 1 mg, for intravenous use J1602 Office 12 10,484 $93,588
Injection, methylprednisolone acetate, 1 mg J1010 Office 111 19,140 $1,803
Injection, methylprednisolone acetate, 40 mg J1030 Office 50 172 $763
Injection, zoledronic acid, 1 mg J3489 Office 13 65 $335

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $212
$212 — —
Cimzia
  • UCB, Inc. $171
$171 88 121,200
RINVOQ
  • AbbVie, Inc. $163
$163 — —
TREMFYA
  • Janssen Biotech, Inc. $150
$150 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $133
$133 81 13,375

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

499 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record